Navigation Links
Gentris Corporation Announces Collaboration to Study Blood Stability
Date:7/26/2012

MORRISVILLE, N.C., July 26, 2012 /PRNewswire/ -- Gentris Corporation (www.gentris.com), a global leader in pharmacogenomics and biorepository solutions, announced today that it will begin a collaborative study with a major pharmaceutical company to test the long-term stability of DNA in whole blood samples that have been stored for five and ten years. This study will provide insight into the optimal, long-term storage of clinical samples to ensure adequate DNA integrity for future pharmacogenomics testing.      

The three phase collaboration aims to investigate the effects of multiple freeze-thaw cycles on DNA from whole blood, both fresh and archived. In order to evaluate these effects, DNA will be extracted from archived whole blood samples after several freeze-thaw cycles and will undergo quantitative genotyping for specific genetic variations. Variants were chosen to evaluate both large and small deletions to assess DNA integrity. The results will be compared to genotyping data from the same samples before long-term storage and to similarly treated, freshly collected blood samples. A pharmaceutical partner will provide archived samples and the associated data. Gentris will provide freshly collected samples and perform the genotyping analysis.

The goal of this collaboration is to determine the impact of long term storage and multiple freeze-thaw cycles on the integrity of DNA from whole blood samples. With this data, Gentris will be able to determine whether archived samples would be best stored as whole blood or extracted DNA to ensure sufficient sample quality for future analysis. Maintaining high-quality samples allows pharmaceutical companies to utilize these biospecimens as needed during the entire drug development process, which typically takes several years to complete.

Related Links: www.gentris.com

Quotes: 
"We look forward to collaborating with our pharmaceutical partner to investigate an important question as more companies establish long-term archives of clinical samples," said Eric Hall, Gentris Vice President of Clinical Operations and Biorepository Services. "Because technologies are improving rapidly and the drug development process is lengthy, pharmaceutical companies can gain significant value from reanalyzing samples in order to refine later phases of clinical trials or answer questions that arise during development. Proper handling and storage of samples is the foundation for driving innovation in pharmacogenomics and personalized medicine."

About Gentris Corporation:
Founded in 2001, Gentris is located in Research Triangle Park, NC, where it provides pharmacogenomics and biorepository support for all phases of clinical studies and genomic biomarker programs.  The Company works with academic and industry leaders to translate innovations in pharmacogenomics into safer, more effective medicines, which can lead to accelerated drug development and improvement in patient care globally.  In the past year, Gentris significantly expanded its facility and onsite biorepository to meet the increased needs of biopharma clients, while maintaining a preeminent quality system.  


'/>"/>
SOURCE Gentris Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gentris Corporation Partners with the Shanghai Institutes of Preventative Medicine
2. Gentris Corporation Launches New Pharmacogenomics Services
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
5. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
6. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
7. Luminex Corporation Reports First Quarter 2012 Results
8. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
9. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
10. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
11. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , February 11, 2016 --> ... of a new research report, titled "Sports Medicine Devices Market ... 2013 - 2019". According to the report, the global sports ... CAGR from 2013 to 2019, growing from a value of ... --> --> The global sports ...
(Date:2/11/2016)... , February 11, 2016 Jeffrey ... Worldwide Clinical Trials, will present at this year,s Summit for ... Hyatt Regency in Miami, FL. Zucker ... to optimize study execution, supporting SCOPE,s "Improving Site Study Activation ... place on Thursday, Feb. 25 at 11:05 a.m. ...
(Date:2/11/2016)... F ast access ... at the point of need ... medical information products and services, has launched a ClinicalKey mobile ... a mobile device. Elsevier designed the mobile app to allow users to ... available in Android and iOS formats for mobile ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... ... Florida Hospital presents Heart Health Awareness night on Sunday February 14th, as ... The puck drops at 6:00pm, but fans will have the opportunity to experience the ... The MEGA Heart will be located on Ford Thunder Alley and provide fans with ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a FY 2017 ... but would shift more of the cost burden to military beneficiaries. , MOAA’s ... in the defense budget as including limited quantifiable benefit fixes mixed with numerous beneficiary ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... discuss how to improve care by making data on heart procedures public and ... Summit on Transparency and Public Reporting of Pediatric and Congenital Heart Disease Outcomes ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, ... Benefit Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. ... with Intel on value-based health benefits program Connected Care, will discuss the challenges ...
(Date:2/11/2016)... ... 11, 2016 , ... "What holds you back from ... a question as a challenge for his readers to examine the full scale ... (published by Partridge Singapore), Clarke explores the subject with more depth, revealing time-honored ...
Breaking Medicine News(10 mins):